Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.55 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.43 |
| ▸ | BRD1 | O95696 | 1/20 | 0.43 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3625634 | 0.99 | HTR6 (0.54) | HTR6TRIM24BRD1BRPF1KAT6A | |
| SCHEMBL3618468 | 0.96 | HTR6 (0.52) | HTR6TRIM24BRD1BRPF1KAT6A | |
| Hydrochloric Acid SCHEMBL3617761 | 0.95 | HTR6 (0.53) | HTR6TRIM24BRD1BRPF1KAT6A | |
| SCHEMBL3611199 | 0.90 | HTR6 (0.53) | HTR6KAT6A | |
| Hydrochloric Acid SCHEMBL6862743 | 0.89 | HTR6 (0.47) | HTR6RIPK2ACVR1NOD2 | |
| Hydrochloric Acid SCHEMBL3622582 | 0.89 | HTR6 (0.53) | HTR6KAT6A | |
| SCHEMBL3622751 | 0.86 | HTR6 (0.63) | HTR6KAT6A | |
| SCHEMBL3615263 | 0.85 | HTR6 (0.57) | HTR6KAT6A | |
| Hydrochloric Acid SCHEMBL3614666 | 0.85 | HTR6 (0.62) | HTR6KAT6A | |
| SCHEMBL3622643 | 0.85 | HTR6 (0.54) | HTR6KAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718650-B2 | Aryl sulfonamide compounds for treating obesity | BIOVITRUM AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-7566715-B2 | Substituted sulfonamide compounds useful for the prophylaxis and treatment of conditions relating to obesity, type II diabetes and/or disorders of the central nervous system | BIOVITRUM AB (SE) | 2009-07-28 | — | — | US | disclosed |
| US-20080096873-A1 | NEW COMPOUNDS | BIOVITRUM AB, A SWEDEN CORPORATION | 2008-04-24 | — | — | US | disclosed |
| US-7319097-B2 | Treatment of type II diabetes with benzenesulfonamide substituted with an N-heterocycle: N-[2-amino-5-(1,4-diazepan-1-yl)phenyl]benzenesulfonamide, N-[4-amino-5-(piperazinyl)phenyl]benzenesulfonamide, 3-amino-4-(5-methyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-N-phenyl-benzenesulfonamide hydrochloride | BIOVITRUM AB (SE) | 2008-01-15 | — | — | US | disclosed |
| US-7173035-B2 | Arylsulfonamide compounds | BIOVITRUM AB (SE) | 2007-02-06 | — | — | US | disclosed |
| US-20060009446-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2006-01-12 | — | — | US | disclosed |
| US-20050288275-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2005-12-29 | — | — | US | disclosed |
| US-6969710-B2 | Compounds | BIOVITRUM AB (SE) | 2005-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009446-A1 | New compounds | GPR119, SULT2A1, STS | HTR6 484/4885TRIM24 4805/4885BRD1 2583/4885 |
| US-20080096873-A1 | NEW COMPOUNDS | GPR119, SULT2A1, STS | HTR6 484/4885TRIM24 4805/4885BRD1 2583/4885 |
| US-20050288275-A1 | New compounds | GPR119, SULT2A1, STS | HTR6 484/4885TRIM24 4805/4885BRD1 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.